Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Alpha Blockade for Pheochromocytoma
NCT03176693Phase 3Completed
- Sponsor
- University of California, Los Angeles
- Start
- May 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of doxazosin in pheochromocytoma and Paraganglioma (PGL) (2 arms), sponsored by University of California, Los Angeles. Primary endpoint: Hemodynamic Instability. Started May 2017; status: completed.
02
Drugs
doxazosin
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT03176693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03176693.